开发一种基于的光免疫疗法药物,向PD-L1
Takuya Otani1, Naoya Kondo1, Ayaka Kanai1
1Near InfraRed Photo-ImmunoTherapy Research Institute, Kansai Medical University, Hirakata 573-1010, Osaka, Japan.
Molecules (Basel, Switzerland)
|January 28, 2026
概括
一种新的类药物针对PD-L1用于近红外光免疫疗法 (NIR-PIT),显示出对癌症治疗的希望. 在临床前研究中,这种新的方法有效地降低了癌细胞的活力,并抑制了瘤的生长.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 生物结合的生物结合
背景情况:
- 近红外光免疫疗法 (NIR-PIT) 提供选择性癌症治疗.
- 目前的NIR-PIT依赖于一种基于抗体的药物,需要探索替代治疗剂.
- 编程死亡配体1 (PD-L1) 在各种癌症中过度表达,使其成为一个可行的治疗标.
研究的目的:
- 开发和评估一种新的基于的药物,用于PD-L1向的NIR-PIT.
- 在体外和体内评估-药物结合物的疗效.
主要方法:
- 结合了PD-L1结合WL12与光吸收器IRDye700DX (IR700) 的结合.
- 在NIR光照射下对PD-L1阳性癌细胞进行WL12-IR700疗效的体外评估.
- 在临床前癌症模型中对瘤生长抑制和生存率的体内评估.
主要成果:
- 在PD-L1阳性癌细胞中,WL12-IR700诱导了光免疫疗法样细胞死亡.
- 癌细胞活力以剂量和度依赖的方式降低.
- 在体内观察到显著的瘤生长抑制和延长的整体存活率.
结论:
- 开发的基于的药物WL12-IR700对PD-L1向的NIR-PIT有效.
- 这种类药物合物代表了PD-L1表达癌症的有前途的替代治疗方式.
相关概念视频
Targets for Drug Action: Overview
10.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.2K
Peptide Bonds
82.8K
A peptide bond covalently attaches amino acids through a dehydration reaction. One amino acid's carboxyl group and another amino acid's amino group combine, releasing a water molecule. The resulting bond is the peptide bond. The products that such linkages form are peptides. As more amino acids join this growing chain, the resulting chain is a polypeptide. Each polypeptide has a free amino group at one end. This end has the N-terminal, or the amino-terminal, and the other end has a free...
82.8K
PD Controller: Design
650
In automotive engineering, car suspension systems often employ Proportional Derivative (PD) controllers to enhance performance. PD controllers are utilized to adjust the damping force in response to road conditions. A controller, acting as an amplifier with a constant gain, demonstrates proportional control, with output directly mirroring input.
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...
650
Time-Domain Interpretation of PD Control
396
Proportional-Derivative (PD) control is a widely used control method in various engineering systems to enhance stability and performance. In a system with only proportional control, common issues include high maximum overshoot and oscillation, observed in both the error signal and its rate of change. This behavior can be divided into three distinct phases: initial overshoot, subsequent undershoot, and gradual stabilization.
Consider the example of control of motor torque. Initially, a positive...
Consider the example of control of motor torque. Initially, a positive...
396
Frequency-Domain Interpretation of PD Control
364
Proportional-Derivative (PD) controllers are widely used in fan control systems to improve stability and performance. A fan control system can be effectively represented using a Bode plot to illustrate the impact of a PD controller through its transfer function. The Bode plot visually conveys how PD control modifies the fan's response across various frequencies, providing a frequency domain interpretation of the controller's behavior.
The proportional control gain, combined with the...
The proportional control gain, combined with the...
364
In Vitro Drug Release Testing: Overview, Development and Validation
327
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
327


